Medical Simulation Medical Graphic
Medical Animation | MOA | Medical Illustration | Holo 3D | General 3D | VideoGame Development | Contact

Erectile Dysfunction Animation

Treatment Animations

Erectile illustrations and treatment option through medical animation studio method of action videos.
Custom 3d animations and hi-def illustrations and hi-def renders created by medical animation studio
Dr Nano
Federal Agents Seize FastSize Extenders And FastSize EQM Erectile Quality Monitors
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized $346,954.43 worth of FastSize Extender devices and FastSize EQM Erectile Quality Monitor devices, as well as component parts used in the manufacture of the FastSize Extender. The FastSize Extender and the FastSize EQM Erectile Quality Monitor are manufactured and distributed by FastSize, LLC of Aliso Viejo, Calif...
Dangers Of Untreated Erectile Dysfunction
Research carried out by a visiting professor at the University of Hertfordshire has found that up to six million European men fail to seek help for Erectile Dysfunction (ED) which could result in underlying cardiovascular disease going undetected...
Increased Risk Of Cardiovascular Problems In Depressed Men With Erectile Dysfunction
A new study in the Journal of Sexual Medicine found that the presence of depressive symptoms in men with erectile dysfunction constitutes a risk factor for a major cardiovascular event. Erectile dysfunction and depressive mood are often associated, and both are associated with an increased risk of cardiovascular disease and death...
Furiex Pharmaceuticals Announces Issuance Of U.S. Patent For Dapoxetine Method Of Treatment
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine. Furiex developed dapoxetine in collaboration with Alza Corporation and its affiliates. U.S. Patent No...
Study Finds Higher STD Rates Among Users Of Erectile Dysfunction Drugs
Physicians who prescribe erectile dysfunction drugs for their male patients should be sure to discuss the importance of safer sex practices, even with older patients: that is an important implication of a report in the July 6 issue of Annals of Internal Medicine. The analysis of insurance records of more than 1.4 million U.S...
NexMed Announces First Patent Allowance For Vitaros(R) In Japan
NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT® technology, announced that the Japanese Patent Office has issued the Decision to Grant a Patent for NexMed's patent application entitled, "Prostaglandin Compositions for the Treatment of Male Erectile Dysfunction...
Erectile Dyfunction - Marker For Heart Attack
Seven out of 10 men admitted to hospital for a heart attack (acute ST segment elevation myocardial infarction (STEMI)) had erectile dysfunction (ED) in the six months prior to their admission according to new data presented at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China...
'Sonic Hedgehog' Helps Regenerate Critical Nerve That Runs Along Prostate, Could Heal Erectile Dysfunction After Surgery
After men have surgery to remove a cancerous prostate gland, up to 80 percent of them will lose the ability to have an erection because of damage to a critical nerve that runs along the prostate. New research from Northwestern University Feinberg School of Medicine shows the damaged nerve can be regenerated more quickly with a protein called sonic hedgehog delivered via a nanofiber gel...
Testosterone To Treat 'Male Menopause' Questionable
Given that it is not clear whether male menopause actually exists, and inconclusive evidence on testosterone's effectiveness in treating it, an article in today's Drug Therapeutics Bulletin (DTB), a BMJ (British Medical Journal) journal, says that the use of synthetic testosterone is questionable...
Physician-Scientists Present At 2010 American Urological Meeting
Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center presented their latest research findings at the American Urological Association's Annual Meeting in San Francisco, May 29 to June 3. Dr. Steven Kaplan, a urologist and professor of urology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and Dr...
Positive Results From Phase 3 Study Of Avanafil In Erectile Dysfunction Presented At AUA Annual Meeting
VIVUS, Inc. (Nasdaq: VVUS) announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting...
Link Established Between Erectile Dysfunction And Calcified Coronary Arteries
In the largest study to date evaluating erectile dysfunction (ED) and coronary artery calcification, researchers at Mount Sinai School of Medicine have determined that men with ED are at a significantly increased risk of high coronary artery calcification scores (CACS), a known predictor of future cardiovascular events...
Pivotal Data For The Investigational Treatment PSD502 For Primary Premature Ejaculation In The U.S. To Be Presented At Meeting
Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco...
Counterfeit ED Drugs Pose Fatal Health Risks
Counterfeit drugs for erectile dysfunction (ED) can contain toxic materials, too much active ingredient or no active ingredient at all and pose serious health risks, according to research presented at the 105th Annual Scientific Meeting of the American Urological Association (AUA)...
Pivotal Data For The Investigational Treatment PSD502 For Primary Premature Ejaculation
Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco...
WindowsFlashQuicktime
Request Demo Reel DVD
Related Medical Animation Links

Copyright © 2010
Content Management / Website Design by Tresware